North America Bladder Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography 2017 - 2022

  • ID: 4388347
  • Report
  • Region: North America, United States
  • 120 pages
  • Mordor Intelligence
1 of 4
Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. It is the ninth most common cancer worldwide in men and women, with the highest recurrence rate. Though there has been development over the past ten years in bladder cancer treatment, a huge void of unmet needs is yet to be filled. The bladder cancer market is currently estimated to be valued at USD 201 million in 2015 and is expected to grow at a CAGR of 2-5%

The North America bladder cancer therapeutics & diagnostic market is segmented based on:


Transitional cell bladder cancer

Invasive bladder cancer

Superficial bladder cancer

Squamous cell bladder cancer

Other rare types




Radiation therapy


Major tests




Urine Cytology

Bladder Ultrasound





North America holds the largest market for bladder cancer treatment drugs due to the availability of better health care solutions and rise in bladder cancer cases in the region. The American Cancer Society’s in 2015, estimates about 74,000 new cases of bladder cancer diagnosed (about 56,320 in men and 17,680 in women) and about 16,000 deaths from bladder cancer (about 11,510 in men and 4,490 in women) in the US region.

Some of the key participants in the industry include Pfizer, GlaxoSmithKline, Sanofi S.A, Roche, Novartis, Eli Lilly and Co, AstraZeneca plc, Bristol-Myers Squibb etc.


Increasing bladder cancer cases

Technological developments

Drug innovations with regard to the bladder cancer

Government initiatives

Rise in aging populace

Advanced health care services

Upsurge in awareness about bladder diseases and their available therapies in the market

Increasing health care expenditure


Rise in the number of patent expirations

Rise in the use of generic drugs

Asymptomatic nature of the disease


The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.


Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Note: Product cover images may vary from those shown
2 of 4
1.1 Market Definition
1.2 Research Methodology
1.3 Markets Covered
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Rise in awareness about bladder diseases and their available therapies
3.1.2 Increasing health care expenditure
3.1.3 Innovation in drug development, and subsequent technological advancements
3.2 Market Restraints
3.2.1 Rise in number of patent expirations
3.2.2 Increase in use of generic drugs
3.2.3 Asymptomatic nature of the disease
3.3 Market Opportunitites
3.4 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 North America Bladder Cancer Therapeutics & Diagnostics Market, by Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive bladder cancer
5.1.4 Squamous cell bladder cancer
5.1.5 Other rare types
5.2 North America Bladder Cancer Therapeutics Market
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Radiation therapy
5.2.4 Surgery
5.3 North America Bladder Cancer Diagnostics Market
5.3.1 Cystoscopy
5.3.2 Biopsy
5.3.3 Urinalysis
5.3.4 Urine Cytology
5.3.5 Bladder Ultrasound
5.4 North America Bladder Cancer Therapeutics & Diagnostics Market, By Region
5.4.1 U.S
5.4.2 Canada
5.4.3 Mexico
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to new market players
7. Company Profiles
7.1 Novartis International AG
7.2 Pfizer Inc
7.3 GlaxoSmithKline plc
7.4 Sanofi S.A
7.5 Eli Lilly and Co
7.6 AstraZeneca plc
7.7 Bristol-Myers Squibb
7.8 F. Hoffmann-La Roche AG
7.9 Celgene Corporation
8. Appendix
8.1. Abbreviations
8.2. Sources
8.3. Bibliography
8.4. Disclaimer
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Note: Product cover images may vary from those shown